
In China, For Global
Provide patients with world-class, trustworthy, affordable, and innovative drugs.
Company at a Glance
Original Innovation, Science Oriented
An innovative and globally competitive biopharmaceutical company with a whole-industry-chain layout.
- Priority programs in development
- 30
- Fermentation capacity at Wujiang and Lingang Phase I
- 46,500
- Countries and regions where toripalimab is approved
- 50







First patient dosed in Phase 3 liver cancer trial of JS207 and JS007
China accepts application for subcutaneous toripalimab in urothelial carcinoma
Final NEOTORCH analysis presented at the ESMO Congress 2026